Digital health companies highlight value of rigorous validation

Digital health is a relatively young area of healthcare, but some companies have been around long enough to prove the value of their technologies in clinical studies over time. That’s also thanks in part to deciding early on to seek FDA clearance for their software as a drug or treatment. In a panel discussion at Health Datapalooza last week, WellDoc Chief Strategy Officer Anand Iyer and Akili Interactive Labs Cofounder and CEO Eddie Martucci offered some insight on how their rigorous approaches have made it easier to demonstrate their products’ value.